Analysts await Loxo Oncology, Inc. (NASDAQ:LOXO) to report earnings on Mar, 15 for the fiscal quarter ending Dec 2015.

They expect $-0.51 EPS, down 100% or $0.51 from last year’s $n/a per share.

At the moment 5 analysts are watching Loxo Oncology, Inc. (NASDAQ:LOXO), 3 rate it “Buy”, 2 “Outperform”, 0 “Underperform”, 0 “Sell”, while 0 “Hold”.

Looking forward, for the quarter ending Mar-16, 1 analyst has a mean sales target of 0.00 million. For the quarter ending Jun-16, 1 analyst has a mean sales target of 0.00 million whilst for the year ending Dec-16, 3 analysts have a mean target of 80.77 million.

In terms of earnings per share, 3 analysts have a -0.51 EPS mean target for the quarter ending Mar-16, for the quarter ending Jun-16, 3 analysts have a -0.53 EPS mean target and for the quarter ending Jun-16 there are 5 estimates of -2.41 EPS.

The biggest institutional shareholders in Loxo Oncology, Inc. include Aisling Capital LLC which owns 4 million shares in the company valued at $108.01 million. Aisling Capital Partners III LLC is the second biggest holder with 3 million shares currently valued at 40.57 million whilst Fidelity Management and Research Company has 3 million shares valued at 96.63 million.

Total shares held by institutions as of the most recent company filings are 22,866,092 with a reported 755,273 bought and 518,754 sold. These holdings make up 90.77% of the company’s outstanding shares.

Currently insiders hold 261,831 shares in the business which makes up 1.57% of shares. The biggest holder currently is Avi Z. Naider who owns 159,118 shares (0.95% of those outstanding), whilst Dr. Dov A. Goldstein, M.D. holds 65,873 (0.39% of shares outstanding) and Dr. Lori Anne Kunkel holds 26,840 (0.16% of shares outstanding).

The stock increased 1.22% or $0.25 during the last trading session.